Long-term study of guselkumab in children who previously took it
Treatments studied
Part of Bones, joints & muscles, Digestive system, Immune system & allergy, Skin clinical trials.
This study is a long-term follow-up for children who have already finished an earlier study of guselkumab, a medicine for skin conditions like psoriasis. It looks at whether staying on the medicine continues to be safe and helpful over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the full treatment plan in the earlier guselkumab study for children.
- Your child's doctor must agree that they have benefited from continuing guselkumab.
- If your child could become pregnant, they must use highly effective birth control during the study and for 12 weeks after the last dose, or not be sexually active.
- Your child cannot be pregnant, nursing, or planning to become pregnant or father a child during the study.
- Your child cannot have used any medications or treatments that are not allowed in this study before starting.
- You and your child (if age 7 or older) must agree to the study rules by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This study looks at how well guselkumab works for people with moderate to severe Crohn's disease or ulcerative colitis when used as part of regular treatment. It gathers information from real patients to see how the drug performs outside of a research setting.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study tracks how well guselkumab (a biologic medication that blocks IL-23, a protein that drives inflammation) works for moderate-to-severe ulcerative colitis or Crohn's disease in everyday clinical practice. Researchers want to understand long-term benefits and safety in real patients.
This study follows people with psoriatic arthritis (joint pain and swelling linked to psoriasis) who are starting a newer medication called guselkumab. Researchers want to learn how long patients continue taking this medicine and how well it works for them.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.